Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00934466 | Study of the Effect of Single Doses of MK2637 and Dextromethorphan on Cerebral Cortex Excitability (2637-008) | PHASE1 | COMPLETED | 15 | — | — | Jul 1, 2009 | Dec 1, 2009 | Jun 24, 2015 | - | — |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | MK2637 120 mg |
| 2 | EXPERIMENTAL | MK2637 50 mg |
| 3 | PLACEBO_COMPARATOR | Placebo |
| 4 | ACTIVE_COMPARATOR | Dextromethorphan 220 mg |
| 5 | ACTIVE_COMPARATOR | Dextromethorphan 110 mg |
| Name | Type | Description |
|---|---|---|
| MK2637 | DRUG | Single dose of 120 mg MK2637 capsules in one of five treatment periods. |
| Comparator: MK2637 | DRUG | Single dose of 50 mg MK2637 capsules in one of five treatment periods. |
| Comparator: Placebo | DRUG | Single dose of placebo only in one of five treatment periods. |
| Comparator: Dextromethorphan | DRUG | Single dose of 220 mg dextromethorphan capsules in one of five treatment periods. |
Inclusion Criteria: * Subject is right-handed * Subject is in good health * Subject is a nonsmoker Exclusion Criteria: * Subject works a night shift * Subject has a history of any illness that might make participation in the study unsafe or confound the study results * Subject has a history of he...